PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-9.79%
Cash & equivalents declining -9.79% while TRVN's grows 105.64%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-9.79%
Below half of TRVN's 105.64%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.77%
Below half of TRVN's 98.60%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-10.21%
≥ 1.5x TRVN's -2.59%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.10%
≥ 1.5x TRVN's -2.24%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-9.71%
Below half of TRVN's 84.80%. Michael Burry sees a potential red flag for stagnation or capital shortage.
3.20%
Less than half of TRVN's -42.56%. David Dodd sees a more disciplined AP approach or lower volume.
-75.32%
Less than half of TRVN's 3.18%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-4.13%
Both TRVN and the company show zero Deferred Revenue (Current) Growth.
No Data
No Data available this quarter, please select a different quarter.
0.52%
Less than half of TRVN's 14.93%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.45%
Above 1.5x TRVN's -2.21%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-1.62%
Less than half of TRVN's 3.28%. David Dodd sees far fewer liability expansions relative to competitor.
7.69%
Less than half of TRVN's 23.62%. David Dodd sees fewer share issuances vs. competitor.
-2.53%
≥ 1.5x TRVN's -1.31%. David Dodd sees higher yoy retained profits than competitor.
-4.62%
Higher AOCI Growth compared to TRVN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-10.53%
Below half TRVN's 101.00%. Michael Burry sees potential underperformance in building shareholder capital.
-9.71%
Below half TRVN's 84.80%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-19.69%
Above 1.5x TRVN's -1.94%. Michael Burry sees a major jump. Investigate leverage rationale.
9.58%
Less than half of TRVN's -124.38%. David Dodd sees better deleveraging or stronger cash buildup than competitor.